UK markets closed

Genfit S.A. (GNFT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.0142+0.3742 (+10.28%)
As of 02:54PM EDT. Market open.
Full screen
Loading interactive chart…
  • GlobeNewswire

    GENFIT Reports First Quarter 2024 Financial Information

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2024 and revenues for the first three months of 2024.1 Cash position As of March 31, 2024, the Company’s cash and cash equivalents amounted to €74.0 million compared with €128.6 million as

  • Globe Newswire

    GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

    Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 Extra-Financial Performance Report (fiscal year 2023). Third edition of the Extra-Financial Performance report Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to

  • GlobeNewswire

    GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

    Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the April 15, 2024 French legal announcements bulletin n°46 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 1